Frontiers in immunology · 2026
The diagnostic and immunomodulatory role of IL-37 in pediatric sepsis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Jin, Zhang Yanling, Sun Changrui, Yang Hao, Song Zhixin, Huang Feiqi, Wu Chunxiang
Аннотация
OBJECTIVE: Sepsis arises from a dysregulated host inflammatory response to infection. The levels and pathogenic role of interleukin-37 (IL-37) in pediatric sepsis remain to be fully elucidated.
METHODS: Serum IL-37 concentrations were measured in two independent cohorts of pediatric patients with sepsis from Chongqing (discovery cohort, n=40) and Sichuan (validation cohort, n=105). The immunomodulatory effects of IL-37 were systematically investigated through: 1) a murine sepsis model (cecal ligation and puncture), and 2) ex vivo experiments using peripheral blood mononuclear cells (PBMCs) from patients under standardized culture conditions.
RESULTS: Admission serum IL-37 levels were significantly higher in pediatric patients with sepsis compared to non-septic patients and healthy controls. To assess its diagnostic potential, ROC curve analyses were performed, yielding areas under the curve (AUC) of 0.76 [P<0.0001; 95% confidence interval (95% CI), 0.66 - 0.85] and 0.77 [P<0.0001; 95% CI, 0.71 - 0.84] from the two medical centers. In septic mice, therapeutic administration of recombinant IL-37 significantly attenuated systemic inflammation (reduced IL-6, CXCL-1, CCL-2; increased IL-10), decreased the proportion of M1 macrophages without altering total macrophage counts in peritoneal lavage fluids (PLF), and improved survival rates. In vitro, IL-37 neutralization with a specific antibody in septic PBMCs increased the percentages of CD4+ T cells and NKT cells.
CONCLUSION: This study identifies elevated IL-37 as a potential diagnostic biomarker for pediatric sepsis and demonstrates its role in modulating hyperinflammation and immune cell differentiation. IL-37 represents a promising therapeutic target for pediatric sepsis.
METHODS: Serum IL-37 concentrations were measured in two independent cohorts of pediatric patients with sepsis from Chongqing (discovery cohort, n=40) and Sichuan (validation cohort, n=105). The immunomodulatory effects of IL-37 were systematically investigated through: 1) a murine sepsis model (cecal ligation and puncture), and 2) ex vivo experiments using peripheral blood mononuclear cells (PBMCs) from patients under standardized culture conditions.
RESULTS: Admission serum IL-37 levels were significantly higher in pediatric patients with sepsis compared to non-septic patients and healthy controls. To assess its diagnostic potential, ROC curve analyses were performed, yielding areas under the curve (AUC) of 0.76 [P<0.0001; 95% confidence interval (95% CI), 0.66 - 0.85] and 0.77 [P<0.0001; 95% CI, 0.71 - 0.84] from the two medical centers. In septic mice, therapeutic administration of recombinant IL-37 significantly attenuated systemic inflammation (reduced IL-6, CXCL-1, CCL-2; increased IL-10), decreased the proportion of M1 macrophages without altering total macrophage counts in peritoneal lavage fluids (PLF), and improved survival rates. In vitro, IL-37 neutralization with a specific antibody in septic PBMCs increased the percentages of CD4+ T cells and NKT cells.
CONCLUSION: This study identifies elevated IL-37 as a potential diagnostic biomarker for pediatric sepsis and demonstrates its role in modulating hyperinflammation and immune cell differentiation. IL-37 represents a promising therapeutic target for pediatric sepsis.